MicroRNA-155曾被讨论作为癌症诊断和预后的生物标志物，尽管已经发表了相关研究，但由于数据不足，MicroRNA-155的作用仍不确定。我们在PubMed、Embase和Web of Science数据库中进行文献检索，以获得相关文章和提取数据，评估MicroRNA-155在癌症诊断和预后中的作用。汇总结果显示，MicroRNA-155在癌症诊断中具有显著的诊断价值（曲线下面积为0.90，95%置信区间（CI）为0.87-0.92；敏感性为0.83，95% CI为0.79-0.87；特异性为0.83，95% CI为0.80-0.86），并且在人种（亚洲和高加索）、癌症类型（乳腺癌、肺癌、肝细胞癌、白血病和胰腺导管腺癌）、样本类型（血浆、血清、组织）和样本大小（n>100和n<100）分层后仍然保持不变。在预后方面，组合危险比（HR）显示，MicroRNA-155与总体生存率（HR=1.38，95% CI 1.25-1.54）和无复发生存率（HR=2.13，95% CI 1.65-2.76）显著相关，并且与无进展生存率（HR=1.20，95% CI 1.00-1.44）边界显著相关，但与无疾病生存率（HR=1.14，95% CI 0.70-1.85）不显著相关。总体生存分析的亚组分析显示，MicroRNA-155与种族和样本大小分层后的总体生存率显著相关。然而，在白血病、肺癌和口腔鳞状细胞癌的癌症类型亚组和骨髓和组织的样本类型亚组中，显著相关性得以保持，但在结直肠癌、肝细胞癌和乳腺癌的癌症类型亚组和血浆和血清的样本类型亚组中不显著。这个Meta分析的结果表明，MicroRNA-155在癌症诊断和预后中是一个有价值的生物标志物。©2023作者，独家许可给Springer Nature Switzerland AG。

MicroRNA-155 has been discussed as a biomarker in cancer diagnosis and prognosis. Although relevant studies have been published, the role of microRNA-155 remains uncertain because of insufficient data.We conducted a literature search in PubMed, Embase, and Web of Science databases to obtain relevant articles and extract data to evaluate the role of microRNA-155 in cancer diagnosis and prognosis.The pooled results showed that microRNA-155 presented a remarkable diagnostic value in cancers (area under the curve = 0.90, 95% confidence interval (CI 0.87-0.92; sensitivity = 0.83, 95% CI 0.79-0.87; specificity = 0.83, 95% CI 0.80-0.86), which was maintained in the subgroups stratified by ethnicity (Asian and Caucasian), cancer types (breast cancer, lung cancer, hepatocellular carcinoma, leukemia, and pancreatic ductal adenocarcinoma), sample types (plasma, serum, tissue), and sample size (n >100 and n <100). In prognosis, a combined hazard ratio (HR) showed that microRNA-155 was significantly associated with poor overall survival (HR = 1.38, 95% CI 1.25-1.54) and recurrence-free survival (HR = 2.13, 95% CI 1.65-2.76), and was boundary significant with poor progression-free survival (HR = 1.20, 95% CI 1.00-1.44), but not significant with disease-free survival (HR = 1.14, 95% CI 0.70-1.85). Subgroup analyses in overall survival showed that microRNA-155 was associated with poor overall survival in the subgroups stratified by ethnicity and sample size. However, the significant association was maintained in cancer types subgroups of leukemia, lung cancer, and oral squamous cell carcinoma, but not in colorectal cancer, hepatocellular carcinoma, and breast cancer, and was maintained in sample types subgroups of bone marrow and tissue, but not in plasma and serum.Results from this meta-analysis demonstrated that microRNA-155 was a valuable biomarker in cancer diagnosis and prognosis.© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.